Therapeutically, exploiting this dependency using DDR-targeted agents (ATM, ATR, DNA-PKcs, or PARP inhibitors) is a promising strategy to overcome resistance, as it can tip the balance between the extensive DNA damage induced by SBRT and the tumor’s capacity to repair it. The gene discussed is PRKDC; the disease is neoplasm.